Business
ABVC is an early-stage biotechnology company with seven drug candidates and one medical device under development, all licensed from related parties.
ABVC kept revenue flat and boosted equity, but losses widened and going-concern risk remains.
The read at a glance✓ Audited against SEC data
- Business mix — Early-stage biotech with related-party licensesNote
- Revenue — Revenue flat at $510KNote
- Profitability — Net loss widened to $7.9MWatch
- Cash quality — Cash from operations was -$3.0MWatch
- Balance sheet — Equity improved to $11.1MOK
- Insiders — 0 buys / 0 sellsNote
- Accounting — Beneish no flag; going-concern warningWatch
Leadership changes
From ABVC BIOPHARMA, INC.'s own filings, the day they're filed.
- Howard Doong · Chief Executive Officer · departureeff. 2023-06-21
- Uttam Patil · Chief Financial Officer · appointment
- Uttam Yashwant Patil · CEO · appointment
Latest filings
- 8-K · Company announcement2026-08-27
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-02
- 10-Q · Quarterly report2026-05-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ABVC BIOPHARMA, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.